Invesaro

Stocks Comparison

LivaNova vs TransMedics: revenue, profit, margins and growth compared

LivaNova brought in $1.4B of revenue in fiscal 2025, TransMedics $605.5M in fiscal 2025. Revenue changed by +10.7% at LivaNova and +37.1% at TransMedics on the year before, so TransMedics grew faster. LivaNova kept -17.5% of its revenue as net profit, TransMedics 31.4%. Free cash flow was $173.3M at LivaNova and $133.6M at TransMedics.

Side by side, latest fiscal year

LIVNTMDX
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.4B$605.5M
Revenue growth+10.7%+37.1%
Net income-$242.5M$190.3M
Net margin-17.5%31.4%
Free cash flow$173.3M$133.6M
Free cash flow margin12.5%22.1%
Earnings per share (diluted)-$4.45$4.87
Cash$635.6M$488.9M
Debt$376.1M$10M
Price to earningsn/a17.5
Market value$4.2B$3B
Dividend yieldn/an/a
Rank by revenue in sector#130 of 523 · Health care#182 of 523 · Health care

Over the years

Revenue
LIVN FY2018: $1.1BLIVN FY2019: $1.1BLIVN FY2020: $934.2MLIVN FY2021: $1BLIVN FY2022: $1BLIVN FY2023: $1.2BLIVN FY2024: $1.3BLIVN FY2025: $1.4BTMDX FY2019: $14.7MTMDX FY2019: $25.8MTMDX FY2020: $28.4MTMDX FY2021: $31.4MTMDX FY2022: $93.5MTMDX FY2023: $241.6MTMDX FY2024: $441.5MTMDX FY2025: $605.5MFY18FY19FY20FY21FY22FY23FY24FY25
LIVN $1.4BTMDX $605.5M
Net income
LIVN FY2018: -$189.4MLIVN FY2019: -$157.6MLIVN FY2020: -$348.8MLIVN FY2021: -$135.8MLIVN FY2022: -$86.2MLIVN FY2023: $17.5MLIVN FY2024: $63.2MLIVN FY2025: -$242.5MTMDX FY2019: -$23.8MTMDX FY2019: -$33.5MTMDX FY2020: -$28.7MTMDX FY2021: -$44.2MTMDX FY2022: -$36.2MTMDX FY2023: -$25MTMDX FY2024: $35.5MTMDX FY2025: $190.3MFY18FY19FY20FY21FY22FY23FY24FY25
LIVN -$242.5MTMDX $190.3M
Net margin
LIVN FY2018: -17.1%LIVN FY2019: -14.5%LIVN FY2020: -37.3%LIVN FY2021: -13.1%LIVN FY2022: -8.4%LIVN FY2023: 1.5%LIVN FY2024: 5.0%LIVN FY2025: -17.5%TMDX FY2019: -162.1%TMDX FY2019: -129.8%TMDX FY2020: -101.4%TMDX FY2021: -140.9%TMDX FY2022: -38.8%TMDX FY2023: -10.4%TMDX FY2024: 8.0%TMDX FY2025: 31.4%FY18FY19FY20FY21FY22FY23FY24FY25
LIVN -17.5%TMDX 31.4%
Revenue growth
LIVN FY2019: -2.1%LIVN FY2020: -13.8%LIVN FY2021: +10.8%LIVN FY2022: -1.3%LIVN FY2023: +12.9%LIVN FY2024: +8.7%LIVN FY2025: +10.7%TMDX FY2019: +76.3%TMDX FY2020: +9.7%TMDX FY2021: +10.7%TMDX FY2022: +197.8%TMDX FY2023: +158.5%TMDX FY2024: +82.7%TMDX FY2025: +37.1%FY19FY20FY21FY22FY23FY24FY25
LIVN +10.7%TMDX +37.1%
Free cash flow
LIVN FY2018: $83.3MLIVN FY2019: -$115.8MLIVN FY2020: -$114.4MLIVN FY2021: $77.1MLIVN FY2022: $43.4MLIVN FY2023: $39.9MLIVN FY2024: $135.9MLIVN FY2025: $173.3MTMDX FY2019: -$26.4MTMDX FY2019: -$32.5MTMDX FY2020: -$30.7MTMDX FY2021: -$32.4MTMDX FY2022: -$57.7MTMDX FY2023: -$164.9MTMDX FY2024: -$80.9MTMDX FY2025: $133.6MFY18FY19FY20FY21FY22FY23FY24FY25
LIVN $173.3MTMDX $133.6M

Fiscal years as each company reports them; the two may end in different months.

Questions about LivaNova and TransMedics

Which is bigger by revenue, LivaNova or TransMedics?

LivaNova is bigger by revenue: $1.4B in fiscal 2025, against $605.5M for TransMedics in fiscal 2025.

Which keeps more of its revenue as profit, LivaNova or TransMedics?

LivaNova had a net margin of -17.5% in fiscal 2025; TransMedics had 31.4% in fiscal 2025.

Which grew revenue faster, LivaNova or TransMedics?

In their latest fiscal years revenue changed by +10.7% at LivaNova and +37.1% at TransMedics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies